Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 3300 of 3499 entries
View as:

SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00337194 Org: User:
Start: 04/30/06 End: 10/31/14 Due: 10/31/15

Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data

Phase: N/A Priority: Normal
NCT ID: NCT00341939 Org: User:
Start: 09/07/04 End: 06/12/24 Due: 06/12/25

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03606967 Org: User:
Start: 04/13/21 End: 11/30/25 Due: 11/30/26

Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03244384 Org: User:
Start: 11/03/17 End: 06/01/25 Due: 06/01/26

Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection

Phase: N/A Priority: Normal
NCT ID: NCT04247282 Org: User:
Start: 06/09/20 End: 06/12/23 Due: 06/12/24

Analysis of NF2 Mutations in Radiation-Related Neural Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00340496 Org: User:
Start: 08/31/96 End: 07/31/06 Due: 07/31/07

Intermittent or Continuous Acetylsalicylic Acid and Gene Expression in the Nasal Tissue of Current Smokers

Phase: N/A Priority: Normal
NCT ID: NCT02123849 Org: User:
Start: 06/30/14 End: 02/28/18 Due: 02/28/19

Follow-Up Study of Kidney Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT00656955 Org: User:
Start: 04/17/08 End: 06/17/20 Due: 06/17/21

Optimal Methods of Disease Detection in Children and Young Adults With Acute Lymphoblastic Leukemia in the Pediatric Oncology Branch

Phase: N/A Priority: Normal
NCT ID: NCT03627208 Org: User:
Start: 08/02/18 End: 04/14/22 Due: 04/14/23

Sorafenib in Treating Patients With Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00096434 Org: User:
Start: 09/30/04 End: - Due: -

Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia

Phase: N/A Priority: Normal
NCT ID: NCT05687149 Org: User:
Start: 03/23/23 End: 12/31/35 Due: 12/31/36

Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00033332 Org: User:
Start: 04/30/02 End: 06/30/06 Due: 06/30/07

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Phase: N/A Priority: Normal
NCT ID: NCT05172258 Org: User:
Start: 07/26/22 End: 06/30/27 Due: 06/30/28

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

Phase: N/A Priority: Normal
NCT ID: NCT06325683 Org: User:
Start: 11/08/24 End: 07/15/28 Due: 07/15/29

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

Phase: N/A Priority: Normal
NCT ID: NCT02567435 Org: User:
Start: 06/01/16 End: 10/16/25 Due: 10/16/26

Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00397384 Org: User:
Start: 01/31/07 End: 06/30/13 Due: 06/30/14

Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00890747 Org: User:
Start: 08/31/09 End: - Due: -

MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01231919 Org: User:
Start: 01/31/11 End: - Due: -

Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00684996 Org: User:
Start: 06/30/08 End: 10/31/10 Due: 10/31/11

Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT03030417 Org: User:
Start: 02/27/17 End: 10/12/23 Due: 10/12/24

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01081262 Org: User:
Start: 10/12/10 End: 03/12/26 Due: 03/12/27

AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00348699 Org: User:
Start: 07/31/06 End: - Due: -

Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02636582 Org: User:
Start: 06/14/16 End: 05/17/23 Due: 05/17/24

Epidemiology of Burkitt Lymphoma in East Africa Children or Minors (EMBLEM)

Phase: N/A Priority: Normal
NCT ID: NCT01196520 Org: User:
Start: 05/25/10 End: 05/21/20 Due: 05/21/21

Biological Specimen Collection for Laboratory Methods Development and Training Purposes

Phase: N/A Priority: Normal
NCT ID: NCT00025831 Org: User:
Start: 10/31/01 End: 09/30/05 Due: 09/30/06